Is the FDA’s decision to delay Sarepta drug decision good or bad? Nobody really knows
May 25, 2016 at 14:52 PM EDT
Eteplirsen, if approved, would be the only treatment for the rare disease Duchenne muscular dystrophy.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|